Eton Pharmaceuticals relaunched HEMANGEOL, the only FDA-approved treatment for infantile hemangioma, exclusively through Anovo Specialty Pharmacy with integrated Eton Cares patient support including $0 co-pay for eligible patients.
Key takeaways
HEMANGEOL relaunched exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiation.
Eton Cares offers $0 co-pay for eligible commercially insured patients and expanded patient assistance programs.
HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma requiring systemic therapy.
Approximately 5,000-10,000 infants treated annually in the US.
Treatment typically initiated between five weeks to five months of age for about six months.
Company has ten commercial rare disease products including HEMANGEOL.